A detailed history of Vanguard Group Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,809,552 shares of APLS stock, worth $274 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,809,552
Previous 9,505,866 3.19%
Holding current value
$274 Million
Previous $559 Million 32.65%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$38.07 - $59.71 $11.6 Million - $18.1 Million
303,686 Added 3.19%
9,809,552 $376 Million
Q1 2024

May 10, 2024

SELL
$55.39 - $72.47 $2.76 Million - $3.61 Million
-49,812 Reduced 0.52%
9,505,866 $559 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $3.18 Million - $5.56 Million
85,701 Added 0.9%
9,555,678 $572 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $1.62 Million - $6.13 Million
68,687 Added 0.73%
9,469,977 $360 Million
Q2 2023

Aug 14, 2023

SELL
$76.68 - $93.31 $9.79 Million - $11.9 Million
-127,654 Reduced 1.34%
9,401,290 $856 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $14.7 Million - $21.2 Million
316,453 Added 3.44%
9,528,944 $629 Million
Q4 2022

Feb 10, 2023

BUY
$43.24 - $61.04 $7.84 Million - $11.1 Million
181,412 Added 2.01%
9,212,491 $476 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $13.6 Million - $21.2 Million
304,334 Added 3.49%
9,031,079 $617 Million
Q2 2022

Aug 12, 2022

BUY
$35.07 - $59.21 $5.53 Million - $9.33 Million
157,575 Added 1.84%
8,726,745 $395 Million
Q1 2022

May 13, 2022

BUY
$35.46 - $54.12 $23.1 Million - $35.3 Million
652,071 Added 8.24%
8,569,170 $435 Million
Q4 2021

Feb 14, 2022

BUY
$30.74 - $49.16 $35.8 Million - $57.3 Million
1,164,814 Added 17.25%
7,917,099 $374 Million
Q3 2021

Nov 12, 2021

BUY
$31.4 - $69.84 $12.8 Million - $28.5 Million
407,829 Added 6.43%
6,752,285 $223 Million
Q2 2021

Aug 13, 2021

BUY
$40.9 - $64.9 $259 Million - $412 Million
6,344,456 New
6,344,456 $401 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.07B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.